How can South Africa fight cervical cancer?

Mia Malan
Health editor, Mail & Guardian
Share:
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale

One in 30 women in sub-Saharan Africa will develop cervical cancer, despite it being the most preventable form of female cancer in the world, according to World Health Organisation statistics.

Cervical cancer, which the Medical Research Council says is the most common cancer among South African women, is caused by the sexually-transmitted human papilloma virus (HPV).

“We are very concerned about sexually active women [in South Africa] who are breadwinners for their families. It is so tragic to see women like this suffering and dying from a disease that is entirely preventable,” says Bridgette Goeieman, the cervical cancer programme manager of the health organisation, Right to Care, which is based at Helen Joseph Hospital in Johannesburg.

According to Goeieman, up to 80% of women infected with HPV don’t develop cancer with their “immune systems clearing it out naturally”. “But 20% will have persistent infection, which can lead to a lesion which will result in cancer if there’s no intervention.”

Cervical cancer can be prevented through regular pap smears, which can identify pre-cancer lesions in the cervix which can then be treated before they develop to cancer. “But South Africa’s cervical cancer prevention strategies in the public health sector are not well implemented and patients are badly informed about them. As a result, patients don’t access pap smears in time,” says Goeieman.

In line with World Health Organisation guidelines, state health facilities in South Africa offer sexually-active women of 30 years and older, with uncompromised immune systems, one pap smear every 10 years. “Cervical cancer progresses slowly – it takes about ten years from HPV infection to cancer – which is what the guidelines are based on,” says Goeieman.

In HIV-positive women, however, it develops “much more aggressively and in only two to five years”.  Pap smears are therefore offered more regularly to such women, depending on their treatment results.

But Goeieman says nurses at understaffed primary healthcare clinics are overwhelmed, which often leads to such facilities dedicating only one day per week to pap smears. “So if a woman comes to a clinic for her hypertensive treatment on say, a Tuesday, they’ll tell her we only do pap smears on Thursdays. Obviously, that woman, who took a day off work, is not going to come back,” she says. “Nurses also complain that the procedure is time-consuming [15 minutes] compared to other procedures and they don’t have sterilising equipment or dedicated rooms to perform pap smears in.”

In the private sector, where pap smears are easily accessible to women who can afford them, the turnaround time for results are about three days, whereas it can take up to six weeks in the public health sector.

In February last year, the health department introduced an HPV vaccine free of charge to all nine- and ten-year-old school girls. The vaccine is 90% effective against the two most common cancer-causing HPV strains in women who have not yet contracted the virus. “But the impact of the vaccines will only be felt in about 10 to 15 years from now, when those girls have become adults who hadn’t developed cervical cancer as a result of the vaccine,” Goeieman says.

This article is published in collaboration with Mail & Guardian. Publication does not imply endorsement of views by the World Economic Forum.

To keep up with the Agenda subscribe to our weekly newsletter.

Author: Mia Malan is the health editor and heads up the health journalism centre, Bhekisisa.

Image: Cancer cells are seen under a microscope. REUTERS 

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum